Agent
Muvalaplin (LY3473329)
Status Phase 3 outcomes (MOVE-Lp(a), n=10,450, recruiting)
The first oral Lp(a)-lowering agent: a small molecule that blocks the assembly of apo(a) with apoB100 while sparing plasminogen. Up to 65 percent lowering in 14 days in phase 1 (JAMA 2023, single site in the Netherlands) and 82 to 86 percent at 60 to 240 mg daily on an intact-particle assay in KRAKEN (JAMA 2025). MOVE-Lp(a) started September 2025 and runs to 2031.
Measurement note. Traditional apo(a)-based immunoassays detect the free apo(a) that muvalaplin leaves in circulation and therefore under-read its effect (about 70 percent vs 86 percent); intact-particle assays are needed to judge it (see Nicholls, JAMA 2025 and the J Lipid Res 2025 assay paper).
oral inhibitionoralsmall molecule
Page updated 17 August 2026.